The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Growth In Market Value Is Anticipated For The Acromegaly Market Between 2026 And 2030?

The market for acromegaly treatments has seen rapid expansion in recent years. It is anticipated to increase from $2.56 billion in 2025 to $3.01 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.5%. Historically, this growth can be ascribed to the limited availability of acromegaly diagnostic tools, a rising prevalence of growth hormone disorders, an expanding hospital and specialty clinic infrastructure, the adoption of conventional treatment methods, and increasing awareness of rare endocrine disorders.

The acromegaly market is projected to experience substantial expansion over the upcoming years. It is anticipated to reach a valuation of $5.84 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 18.1%. This projected growth is driven by factors such as the advancement of sophisticated somatostatin analogues, an increase in parenteral treatment alternatives, the growing embrace of precision medicine strategies, the rise of homecare and outpatient treatment paradigms, and the incorporation of digital health and remote monitoring technologies. Key trends anticipated within this period encompass the increased uptake of growth hormone measurement and IGF-I testing, a surge in the utilization of somatostatin analogues and dopamine agonists, the broadening scope of minimally invasive surgery and radiation therapy, an intensifying emphasis on tailored treatment regimens for patients, and improved awareness and initiatives for early diagnosis.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12913&type=smp

What Influential Factors Are Boosting The Acromegaly Market Demand?

The rising occurrence of hormonal ailments, such as diabetes, is projected to stimulate expansion within the acromegaly market. Hormonal diseases, also termed endocrine disorders, represent health conditions that emerge from a malfunction in the endocrine system. Diabetes is recognized as one of the most widespread and significant hormonal diseases. Acromegaly and various other endocrine conditions can arise from the excessive production of certain hormones, including growth hormone or cortisol. Additionally, due to the influence of high levels of growth hormone on insulin synthesis, around 50% of individuals suffering from acromegaly may develop insulin resistance or type 2 diabetes mellitus. For instance, in March 2024, data from the Office for Health Improvement and Disparities, a UK-based government department, indicated that from March 2022 to March 2023, the percentage of people with type 1 diabetes who received all eight recommended care processes increased by 22%, while for type 2 diabetes, this percentage grew by 21%. During the same period, the percentage achieving target HbA1c levels climbed to 37.9%, representing the highest value ever reported by the National Diabetes Audit (NDA). Therefore, the increasing number of hormonal diseases is propelling the growth of the acromegaly market.

What Are The Major Segment Categories Within The Acromegaly Market?

The acromegaly market covered in this report is segmented –

1) By Type: Ectopic Acromegaly, Acromegaly Due To Growth Hormone

2) By Diagnosis: GH And IGF-I Measurement, Growth Hormone Suppression Test, Imaging, Other Diagnosis

3) By Route Of Administration: Oral, Parental, Other Routes Of Administration

4) By Treatment: Medication, Somatostatin analogues, Dopamine Agonists, Growth Hormone Antagonist, Surgery, Radiation, Other Treatments

5) By End Users: Hospitals, Specialty Clinics, Other End Users

Subsegments:

1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly, Non-Tumor-Induced Ectopic Acromegaly

2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess, Secondary Growth Hormone Excess

What Trends Are Affecting The Growth Of The Acromegaly Market?

Companies operating within the acromegaly market are primarily focused on developing innovative products and solutions, such as generic lanreotide, to improve treatment options and patient outcomes. Generic lanreotide refers to an unbranded formulation of the medicine used for treating acromegaly and certain neuroendocrine tumors. It functions as a somatostatin analogue, effectively reducing growth hormone secretion and enhancing patient accessibility to effective treatment options. For example, in October 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company concentrating on generic drugs, launched the first and only generic version of Sandostatin LAR Depot in the United States. This injectable suspension, octreotide acetate, is indicated for addressing acromegaly and severe diarrhea associated with carcinoid syndrome. This launch significantly improves access to crucial therapy for patients requiring these treatments.

Who Are The Firms Contributing To The Acromegaly Market Ecosystem?

Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc , Strongbridge Biopharma plc, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

Access The Complete Acromegaly Market Report:

https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report

Which Region Accounts For The Highest Share Of The Acromegaly Market?

North America was the largest region in the acromegaly market in 2025. The regions covered in the acromegaly market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Acromegaly Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12913&type=smp

Browse Through More Reports Similar to the Global Acromegaly Market 2026, By The Business Research Company

Thrombophilia Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report

Hormone Therapy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Mastopexy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/mastopexy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model